Northland in Latin America

In Latin America, particularly growth economies like Brazil, two challenges pose the largest risk to population health:  first, the constant shortage of medications as population growth has outpaced regional production capacity and, secondly, the shift of production from necessary antibiotics for rural areas to more focused cardiovascular medications for urban centers that now approach first world economies. Facility maintenance and subsequent quality control of medication is compromised as manufacturers utilize substandard production methods in an attempt to meet ever increasing pharmaceutical demand. This compromised quality then effects downstream supply chain as evident by drug instability, early expiration, and ultimately low efficacy.

Latin America’s rural areas suffer from shortages of common antibiotics (Isoniazid, Azithromycin, Ciprofloxacin, Albendazole, Cephalosporins, Penicillin etc) whereas developing urban centers are experiencing a wider shortage in metabolic (Metformin, Insulin, Glyburide) and cardiovascular (Furosemide, Lisinopril, Amiodarone) medications.  The World Health Organization estimates a continued shift of production from antibiotics to cardiovascular and metabolic/diabetic drugs as the purchasing power of the urban population will drive this shift in manufacturing.

Northland Bioscience, via its subsidiaries NBS Pharmaceuticals and NBS Medical, possesses the necessary production capacity and supply chain forecasting to provide a continuous supply of medications to the region. We work closely with local healthcare agencies to accurately assess product needs of a region; adjusting our manufacturing to help fill anticipated demand of specific products. Our highly trained staff not only monitor production quality but also work closely with the local communities to educate on proper storage, distribution, and administration of our products.